Director at Adicet Bio (NASDAQ: ACET) receives 4,200 stock options grant
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Adicet Bio director Steve Dubin received a new stock option grant covering 4,200 shares of common stock. The option has an exercise price of $8.10 per share and expires on June 20, 2036. It was awarded as compensation rather than through an open-market purchase or sale.
The option will vest in full on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders, as long as Dubin continues serving on the board. Following this grant, he holds 4,200 option shares related to this award.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
DUBIN STEVE
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 4,200 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 4,200 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Option grant size: 4,200 shares
Exercise price: $8.10 per share
Expiration date: June 20, 2036
+1 more
4 metrics
Option grant size
4,200 shares
Underlying common stock in new option grant
Exercise price
$8.10 per share
Strike price of granted stock options
Expiration date
June 20, 2036
Option term end for granted award
Post-grant option holdings
4,200 shares
Total shares subject to this option after grant
Key Terms
Stock Option (Right to Buy), exercise price, expiration date, vest in full, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
exercise price financial
"conversion_or_exercise_price: "8.1000""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: "2036-06-20T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
vest in full financial
"These shares shall vest in full on the earlier to occur of"
annual meeting of stockholders financial
"the date of the next annual meeting of stockholders following the grant date"
FAQ
What insider transaction did Adicet Bio (ACET) report for Steve Dubin?
Adicet Bio reported a grant of stock options to director Steve Dubin for 4,200 underlying common shares. The options were awarded at an exercise price of $8.10 per share as part of his board compensation, not through an open-market trade.
What are the key terms of Steve Dubin’s new Adicet Bio (ACET) stock options?
Steve Dubin received options to acquire 4,200 Adicet Bio common shares at $8.10 per share, expiring June 20, 2036. These options were granted for no cash cost at grant and represent a compensation-related award linked to his board service.
How and when do Steve Dubin’s Adicet Bio (ACET) options vest?
The options vest in full on the earlier of the first anniversary of the grant date or the next annual stockholder meeting. Vesting is conditioned on Steve Dubin’s continued service on Adicet Bio’s board of directors through that vesting date under the grant terms.
What is Steve Dubin’s position in the newly granted Adicet Bio (ACET) options?
Following the grant, Steve Dubin holds 4,200 option shares associated with this award. These options give him the right to buy Adicet Bio common stock at $8.10 per share before their June 20, 2036 expiration, once they are fully vested.